Pd17-02 pivotal Trial of Mri-Guided Transurethral Ultrasound Ablation in Men With Localized Prostate Cancer: Two-Year Follow-Up

Eggener, Scott E.; Koch, Michaël; Penson, David F.; Pavlovich, Christian P.; Chin, Joseph L.; Lotan, Yair; Raman, Steven; Hatiboglu, Gencay; Oto, Aytekin; Relle, James; Fütterer, Jurgen J.; Serrallach, Marc; Heidenreich, Axel; Haider, Masoom A.; Bonekamp, David; Tirkes, Temel; Arora, Sandeep; Zagaja, Gregory P.; Sedelaar, Michiel; Macura, Katarzyna J.; Costa, Daniel; Persigehl, Thorsten; Purysko, Andrei S.; Klotz, Laurence

doi:10.1097/ju.0000000000000860.02

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 8–10 The lower bound of the range was derived from whole-gland ablation plans at 24-month follow-up. There were two intent-to-treat cohorts including men with primary PCa: a prospective pivotal study with a 2-year follow-up ( n = 115), 8 , 9 and a retrospective clinical service report ( n = 47), with follow-up at a median (IQR) of 16 (12–22) months. 10 …”

Section: Evidence Synthesis and Resultsmentioning

confidence: 99%

“…A 21% rate of clinically significant disease was reported on a 1-year, 10-core systematic, transrectal ultrasound-guided biopsy, with 7% of men proceeding to salvage treatment by 2 years. 8 , 9 In the clinical service report, men received biopsy as clinically indicated. Overall, 14/52 men (27%) in that report had a positive finding on MRI at follow-up, and 9/52 (17%) were biopsied.…”

Section: Evidence Synthesis and Resultsmentioning

confidence: 99%

“… 18 , 19 The feasibility of a variety of salvage treatments has been demonstrated: a second TULSA (7), RP (5), EBRT (3), and brachytherapy (1). 9 , 10 , 20 A report assessing the technical feasibility and safety of salvage RP after TULSA in four men concludes that the operative difficulty and perioperative morbidity were negligible when using an open approach to facilitate access to the perineum and rectum. 20 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer: A Systematic Review

Dora

Clarke

Frey

et al. 2022

Journal of Endourology

View full text Add to dashboard Cite

Purpose: MRI-guided transurethral ultrasound ablation (TULSA) uses real-time MR thermometry feedback to target prostate disease. We systematically review the literature to synthesize efficacy, functional, and safety outcomes and assess the influence of planned ablation fraction on outcome. Materials and Methods: PubMed, Embase, and the Cochrane Library were searched from inception to June 2021 following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Studies reporting at least one efficacy, functional, or safety outcome after a single TULSA treatment were included. The relationship of freedom from salvage treatment and potency preservation with planned ablation volume was modeled. Results: Two hundred twenty-four patients were treated in 10 studies with up to a 5-year follow-up, mainly for primary localized prostate cancer (PCa) plus smaller cohorts with recurrent PCa, and locally advanced PCa (LAPC). The prostate-specific antigen decline from baseline up to 2 years, including focal to whole-gland ablation plans, was 54% to 97%. The rate of salvage treatment after one TULSA treatment for primary PCa was 7% to 17%. Continence and potency preservation were from 92% to 100% and from 75% to 98%. Urinary symptoms were stable in men with good voiding function at baseline, and 85% of men with concurrent PCa and lower urinary tract symptoms met the criteria for improvement. Symptom relief in a small cohort of men with LAPC was observed. Grade III adverse events were incurred by 13/224 men (6%), with no rectal injury/fistula or Grade IV complication. The planned ablation fraction was linearly related to salvage-free survival. The relationship between potency preservation and planned ablation fraction followed a sigmoid curve. Conclusions: As an alternative to conventional treatments, TULSA is safe and effective for prostate tissue ablation in men with primary PCa. There is also evidence that TULSA delivers effective relief of urinary symptoms while treating PCa in a single, low-morbidity procedure. The likelihood of freedom from additional treatment or potency preservation is associated with the planned ablation fraction.

show abstract

Section: Evidence Synthesis and Resultsmentioning

confidence: 99%

Section: Evidence Synthesis and Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer: A Systematic Review

Dora

Clarke

Frey

et al. 2022

Journal of Endourology

View full text Add to dashboard Cite

show abstract

“…A follow-up biopsy performed 12 months after the ablation was negative for cancer of patients who underwent TULSA needed salvage treatment. Safety-wise, at 5 years, 92% of patients had pad-free continence, and 87% preserved erectile function [40]. Nonetheless, adequate patient selection for TULSA and the longterm effectiveness of focal therapy delivered by TULSA on hard outcomes remain to be established.…”

Section: Transurethral Ultrasound Mr-guided Ablationmentioning

confidence: 99%

Emerging and anticipated innovations in prostate cancer MRI and their impact on patient care

Correia,

Baydoun,

et al. 2024

Abdom Radiol

View full text Add to dashboard Cite

Prostate cancer (PCa) remains the leading malignancy affecting men, with over 3 million men living with the disease in the US, and an estimated 288,000 new cases and almost 35,000 deaths in 2023 in the United States alone. Over the last few decades, imaging has been a cornerstone in PCa care, with a crucial role in the detection, staging, and assessment of PCa recurrence or by guiding diagnostic or therapeutic interventions. To improve diagnostic accuracy and outcomes in PCa care, remarkable advancements have been made to different imaging modalities in recent years. This paper focuses on reviewing the main innovations in the field of PCa magnetic resonance imaging, including MRI protocols, MRI-guided procedural interventions, artificial intelligence algorithms and positron emission tomography, which may impact PCa care in the future.

show abstract

Targeted MRI-guided transurethral ultrasound ablation (TULSA) treatment of prostate cancer and concordant benign prostatic hyperplasia: results of a single-center retrospective study

Samun

Lumiani²,

Sroka

et al. 2022

Optical Interactions With Tissue and Cells XXXIII; And Advanced Photonics in Urology

View full text Add to dashboard Cite

Pd17-02 pivotal Trial of Mri-Guided Transurethral Ultrasound Ablation in Men With Localized Prostate Cancer: Two-Year Follow-Up

Abstract: INTRODUCTION AND OBJECTIVE: MRI-guided transurethral ultrasound ablation (TULSA) is a minimally-invasive procedure for customized ablation of benign and malignant prostate tissue. We

Cited by 4 publications

References 0 publications

Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer: A Systematic Review

Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer: A Systematic Review

Emerging and anticipated innovations in prostate cancer MRI and their impact on patient care

Targeted MRI-guided transurethral ultrasound ablation (TULSA) treatment of prostate cancer and concordant benign prostatic hyperplasia: results of a single-center retrospective study

Contact Info

Product

Resources

About